{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:14:15Z","timestamp":1794003255811,"version":"4.8.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173822"],"award-info":[{"award-number":["82173822"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021160","name":"Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021160","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB1060000"],"award-info":[{"award-number":["XDB1060000"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejphar.2026.178707","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T15:58:56Z","timestamp":1772294336000},"page":"178707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["PDE4 inhibitor DC591017 ameliorates pulmonary fibrosis through modulating fibroblasts-epithelial cells-alternatively activated macrophages crosstalk"],"prefix":"10.1016","volume":"1019","author":[{"given":"Shuyue","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhen","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2662-217X","authenticated-orcid":false,"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178707_bib1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2026.178707_bib2","doi-asserted-by":"crossref","first-page":"L332","DOI":"10.1152\/ajplung.00384.2003","article-title":"Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers","volume":"287","author":"Barber","year":"2004","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejphar.2026.178707_bib3","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.124.001895","article-title":"Pharmacokinetics and absorption, distribution, metabolism and excretion profiling of tanimilast following an intravenous (14)C-microtracer coadministered with an inhaled dose in healthy male individuals","volume":"53","author":"Bassi","year":"2025","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2026.178707_bib4","article-title":"Roflumilast (Daliresp\u00ae) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial","volume":"38","author":"Baughman","year":"2021","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.ejphar.2026.178707_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1164\/rccm.201301-0021PP","article-title":"Phosphodiesterase-4 inhibitor therapy for lung diseases","volume":"188","author":"Begh\u00e8","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2026.178707_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01805-2016","article-title":"The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease","volume":"50","author":"Burgstaller","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2026.178707_bib7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1164\/rccm.202308-1355LE","article-title":"Pharmacological interpretation of the efficacy of ensifentrine in chronic obstructive pulmonary disease: insights from ENHANCE trials","volume":"209","author":"Calzetta","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2026.178707_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2013.00173","article-title":"The epithelium in idiopathic pulmonary fibrosis: breaking the barrier","volume":"4","author":"Camelo","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178707_bib9","first-page":"119","article-title":"Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases","volume":"43","author":"Castelino","year":"2025","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejphar.2026.178707_bib10","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.7150\/thno.94482","article-title":"Nicotinamide phosphoribosyltransferase prompts bleomycin-induced pulmonary fibrosis by driving macrophage M2 polarization in mice","volume":"14","author":"Chen","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2026.178707_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/thoraxjnl-2013-204596","article-title":"Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis","volume":"70","author":"DePianto","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.ejphar.2026.178707_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.740803","article-title":"Tanimilast, A novel inhaled Pde4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease","volume":"12","author":"Facchinetti","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178707_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/mps6010014","article-title":"Optimized protocol for isolation and culture of murine neonatal primary lung fibroblasts","volume":"6","author":"Fuentes-Mateos","year":"2023","journal-title":"Methods Protoc."},{"key":"10.1016\/j.ejphar.2026.178707_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838449","article-title":"BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis","volume":"13","author":"Herrmann","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178707_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.rmed.2018.12.015","article-title":"Inflammation and immunity in IPF pathogenesis and treatment","volume":"147","author":"Heukels","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejphar.2026.178707_bib16","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202305086","article-title":"Inducible tricolor reporter mouse for parallel imaging of lysosomes, mitochondria, and microtubules","volume":"223","author":"Hutchison","year":"2024","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejphar.2026.178707_bib17","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.21037\/jtd.2017.03.116","article-title":"Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases","volume":"9","author":"Kawamatawong","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ejphar.2026.178707_bib18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13578-024-01320-7","article-title":"CXCL11 reprograms M2-biased macrophage polarization to alleviate pulmonary fibrosis in mice","volume":"14","author":"Kim","year":"2024","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ejphar.2026.178707_bib19","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178707_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0206-2022","article-title":"Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis","volume":"32","author":"Kolb","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.ejphar.2026.178707_bib21","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.molmed.2023.08.010","article-title":"Pulmonary fibrosis: from pathogenesis to clinical decision-making","volume":"29","author":"Koudstaal","year":"2023","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejphar.2026.178707_bib22","doi-asserted-by":"crossref","DOI":"10.2174\/0118743064340418241021095046","article-title":"PDE4 inhibitors and their potential combinations for the treatment of chronic obstructive pulmonary disease: a narrative review","volume":"18","author":"Kumar","year":"2024","journal-title":"Open Respir. Med. J."},{"key":"10.1016\/j.ejphar.2026.178707_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113958","article-title":"DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling","volume":"177","author":"Li","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178707_bib24","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178707_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116282","article-title":"Selpercatinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-\u03b21 signaling pathway","volume":"225","author":"Li","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178707_bib26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1021\/acs.jcim.4c02011","article-title":"Identification of a potent CDK8 inhibitor using structure-based virtual screening","volume":"65","author":"Lin","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejphar.2026.178707_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pccm.2025.02.001","article-title":"Advances in idiopathic pulmonary fibrosis diagnosis and treatment","volume":"3","author":"Liu","year":"2025","journal-title":"Chinese Med. J. Pulmonary Critical Care Med."},{"key":"10.1016\/j.ejphar.2026.178707_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14728214.2024.2340723","article-title":"Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials","volume":"29","author":"MacIsaac","year":"2024","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejphar.2026.178707_bib29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2016-210189","article-title":"Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages","volume":"76","author":"Maier","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2026.178707_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2466-8-17","article-title":"Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice","volume":"8","author":"Martorana","year":"2008","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.ejphar.2026.178707_bib31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1164\/rccm.202406-1208ED","article-title":"Decoding molecular heterogeneity in idiopathic pulmonary fibrosis","volume":"210","author":"Matson","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2026.178707_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173508","article-title":"A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung","volume":"885","author":"Matsuhira","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178707_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71293-3","article-title":"In-vivo lung fibrosis staging in a bleomycin-mouse model: a new micro-CT guided densitometric approach","volume":"10","author":"Mecozzi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.178707_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512393","article-title":"Prostaglandin E2 (PGE2) and roflumilast involvement in IPF progression","volume":"24","author":"Moshkovitz","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178707_bib35","series-title":"Targeting Enzymes in the Brain","first-page":"159","article-title":"Phosphodiesterase 4 (PDE4) and neurological disorders: a promising frontier in neuropharmacology","author":"Nahid","year":"2025"},{"key":"10.1016\/j.ejphar.2026.178707_bib36","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/s12964-024-01925-y","article-title":"The role of epithelial-mesenchymal transition in pulmonary fibrosis: lessons from idiopathic pulmonary fibrosis and COVID-19","volume":"22","author":"Niayesh-Mehr","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejphar.2026.178707_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1504556","article-title":"Uvaol attenuates TGF-\u03b21-induced epithelial-mesenchymal transition in human alveolar epithelial cells by modulating expression and membrane localization of \u03b2-catenin","volume":"15","author":"Patr\u00edcia Gon\u00e7alves Ten\u00f3rio","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178707_bib38","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41419-020-03178-2","article-title":"Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-\u03baB\/NLRP3-mediated epithelial\u2013mesenchymal transition and inflammation","volume":"11","author":"Peng","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2026.178707_bib39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fphar.2020.00259","article-title":"Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases","volume":"11","author":"Phillips","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178707_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242317017","article-title":"PDE4 phosphodiesterases in cardiovascular diseases: key pathophysiological players and potential therapeutic targets","volume":"24","author":"Puertas-Umbert","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178707_bib41","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2026.178707_bib42","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178707_bib43","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178707_bib44","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1165\/rcmb.2022-0304OC","article-title":"Angiopoietin-like 4 is a critical regulator of fibroblasts during pulmonary fibrosis development","volume":"69","author":"Saito","year":"2023","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejphar.2026.178707_bib45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/medicina55040083","article-title":"Epithelial\u2013mesenchymal transition in the pathogenesis of idiopathic pulmonary fibrosis","volume":"55","author":"Salton","year":"2019","journal-title":"Medicina"},{"key":"10.1016\/j.ejphar.2026.178707_bib46","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13753","article-title":"Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury","volume":"6","author":"Sisson","year":"2018","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.ejphar.2026.178707_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107798","article-title":"Idiopathic pulmonary fibrosis: disease mechanisms and drug development","volume":"222","author":"Spagnolo","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2026.178707_bib48","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.ajpath.2020.09.001","article-title":"Pathology of idiopathic pulmonary fibrosis assessed by a combination of microcomputed tomography, histology, and immunohistochemistry","volume":"190","author":"Tanabe","year":"2020","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2026.178707_bib49","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1513\/AnnalsATS.201406-240MG","article-title":"Lung extracellular matrix and fibroblast function","volume":"12","author":"White","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.ejphar.2026.178707_bib50","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2026.178707_bib51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/labinvest.2016.135","article-title":"Fibroblastic foci, covered with alveolar epithelia exhibiting epithelial\u2013mesenchymal transition, destroy alveolar septa by disrupting blood flow in idiopathic pulmonary fibrosis","volume":"97","author":"Yamaguchi","year":"2017","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ejphar.2026.178707_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003121","article-title":"Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort","volume":"9","author":"Zanatta","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ejphar.2026.178707_bib53","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1021\/acs.jmedchem.9b00518","article-title":"Structure-aided identification and optimization of tetrahydro-isoquinolines as novel PDE4 inhibitors leading to discovery of an effective antipsoriasis agent","volume":"62","author":"Zhang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178707_bib54","article-title":"Potential therapeutic targets of macrophages in inhibiting immune damage and fibrotic processes in musculoskeletal diseases","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.178707_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107178","article-title":"IL20Rb aggravates pulmonary fibrosis through enhancing bone marrow derived profibrotic macrophage activation","volume":"203","author":"Zhu","year":"2024","journal-title":"Pharmacol. Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926001895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926001895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:57:40Z","timestamp":1779425860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926001895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":55,"alternative-id":["S0014299926001895"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178707","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PDE4 inhibitor DC591017 ameliorates pulmonary fibrosis through modulating fibroblasts-epithelial cells-alternatively activated macrophages crosstalk","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178707"}}